Noveris Health Sciences is trading 8.33% down at $0.11, with no clear company-specific catalyst identified for September 2, 2026.
- Available market coverage showed no headlines.
- The company’s recent patent and financing announcements predated today’s decline.
- The broader biotech sector and major U.S. indexes are higher, so the move is not clearly tied to sector or overall market weakness.